The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20171853: Warburg Pincus Private Equity XII (NDF) L.P.; Tata Motors Limited
20171876: ICG Strategic Secondaries Fund II LP; Quadriga Capital Private Equity Fund III L.P.
1709002 Informal Interpretation
1709003 Informal Interpretation
1709001 Informal Interpretation
Federal Trade Commission Comment To the Colorado Supreme Court Supporting Amending Colorado's Rules Governing Professional Conduct To Clarify That Attorneys May Advise or Supervise Law Enforcement Officers & Others Engaged In Lawful Undercover Activities
Mars, Incorporated and VCA Inc.; Analysis To Aid Public Comment Proposed Consent Agreement
Total Wine & More
20171811: K3 Private Investors, L.P.; SecureAuth Corporation
20171841: Lindsay Goldberg IV L.P.; WCF Holdings I, LLC
20171854: ArcLight Energy Partners Fund VI, L.P.; Mitsubishi Corporation
20171871: Husky Energy Inc.; Calumet Specialty Products Partners, L.P.
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.